Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 117 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Increasing Education About Cancer Screening and Prevention in Kazakhstan May 11, 2021 New Type of Chemotherapy Bypasses Healthy Cells to Decrease Negative Side... December 5, 2019 Fears breast cancer progress could stall due to COVID-19 backlog June 15, 2021 Beloved Kansas City Jazz Singer Passes Away at 48 After 13-Year... December 3, 2020 Load more HOT NEWS After 5 Years of Follow-Up, the Median PFS Has Yet To... Vegetarian Recipes Death Rates from Ovarian Cancer will Fall in the EU and... A new approach to cancer immunotherapy
